


SR-4835

Chemical Properties

CAS No. :	2387704-62-1
Formula:	C ₂₁ H ₂₀ Cl ₂ N ₁₀ O
Molecular Weight:	499.36
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 (CDK12: IC ₅₀ =99 nM, K _d =98 nM; CDK13: K _d =4.9 nM), which disables triple-negative breast cancer (TNBC) cells
Targets(IC ₅₀)	Apoptosis, CDK

Solubility Information

Solubility	DMSO: 4.8 mg/mL (9.61 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 0.48 mg/mL (0.96 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.96 mg/mL (1.92 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0026 mL	10.0128 mL	20.0256 mL
5 mM	0.4005 mL	2.0026 mL	4.0051 mL
10 mM	0.2003 mL	1.0013 mL	2.0026 mL
50 mM	0.0401 mL	0.2003 mL	0.4005 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. *Cancer Cell*. 2019 Oct 8. pii: S1535-6108(19)30424-6.

Dai W, Wu J, Peng X, et al. CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer. *Clinical and Translational Medicine*. 2022, 12(10): e1087.

Wu Z, Wang M, Li F, et al. CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer. *Frontiers in Molecular Biosciences*. 2021, 8.

Quereda V Bayle S, et al. CDK12/13 Inhibitor SR-4835 Is Active in Triple-Negative Breast Cancer. *Cancer Discov*. 2019 Dec;9(12):1644

Liu S, Wu J, Lu X, et al. Targeting CDK12 obviates the malignant phenotypes of colorectal cancer through the Wnt/ β -catenin signaling pathway. *Experimental Cell Research*. 2023: 113613.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481